CSPG4-Targeting CAR T Cells for Solid Tumor Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments lack effective methods for targeting chondroitin sulfate proteoglycan-4 (CSPG4), a protein highly expressed in aggressive solid tumors like melanoma, mesothelioma, and breast carcinoma, which is associated with tumor migration, invasion, and metastasis, and has limited expression in normal tissues.
Innovation Solution
Development of chimeric antigen receptors (CARs) expressed in immune cells, specifically T cells, that target CSPG4, combining a single-chain variable fragment (scFv) specific for CSPG4 with costimulatory endodomains like CD28, CD27, or 4-1BB, to enhance antitumor activity and persistence, allowing for targeted therapy of CSPG4-expressing cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to target CSPG4, then tumor growth and metastasis can be inhibited, but the treatment lacks long-term persistence and sufficient antitumor efficacy
Solution Approach 1:
The patent combines the antigen-binding domain of monoclonal antibodies with T-cell signaling and costimulatory domains to create chimeric antigen receptors (CARs). This merging allows T cells to directly recognize and bind CSPG4 on tumor cells while providing sustained activation signals, thereby achieving both high antitumor efficacy and long-term persistence of the immune response
Solution Approach 2:
The CAR-modified T cells are designed to autonomously recognize CSPG4-expressing tumor cells and activate antitumor responses without requiring external MHC presentation or additional immune mediators. The cells self-sustain their activity through continuous costimulatory signaling from the CAR structure, enabling long-term persistence and repeated attacks on tumor cells
2Reliability
If CAR-modified T cells are generated to target CSPG4, then long-term persistence and antitumor efficacy are improved, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The CAR structure is divided into distinct functional modules: an extracellular antigen-binding domain derived from monoclonal antibodies, a transmembrane domain for cell surface anchoring, intracellular signaling domains for T-cell activation, and costimulatory endodomains for sustained persistence. This segmentation allows each component to be independently optimized and assembled, simplifying the overall design and manufacturing process despite the complex functionality
Solution Approach 2:
The CAR construct integrates multiple functions into a single receptor molecule: antigen recognition, T-cell activation signaling, and costimulatory signaling for persistence. This multi-functionality eliminates the need for separate molecular components and complex cellular interactions, thereby reducing overall system complexity while achieving enhanced therapeutic effects
3Reliability
If CSPG4 is targeted with CAR-based approach, then treatment effectiveness against solid tumors is improved, but the scope of applicable cancer types needs to be restricted
Solution Approach 1:
The CAR construct uses a universal design that can be applied to target any antigen-expressing cell type. By maintaining the same CAR structure with CSPG4-specific binding domain, the platform achieves high antitumor activity across multiple solid tumor types including melanoma, mesothelioma, and breast carcinoma, demonstrating versatility without compromising effectiveness
Data Source
AI summary
Embodiments of the disclosure include methods and compositions related to chimeric antigen receptors (CAR) that target chondroitin sulfate proteoglycan-4 (CSPG4). T cells transduced with a CSPG4-specific CAR are effective for inhibition of particular cancer cells that express CSPG4. In certain embodiments, the cancer is melanoma, breast cancer, head and neck cancer, mesothelioma, glioblastoma, or renal cancer.